JNJ Johnson & Johnson
Company Analysis
Latest News
🟢 Johnson & Johnson is trading 3.14% up today as election uncertainty eased
Johnson & Johnson is trading 3.14% up at $274.52, with the move appearing mainly driven by improved sentiment as election uncertainty eased. - Democrats...
🟢 Johnson & Johnson is trading 3.27% up in pre-market amid a broad market rally
Johnson & Johnson is trading at $274.87, up +3.27% versus the November 3 close, in line with a broader pre-market rally after Democrats gained control of both...
Johnson & Johnson Reports 93.6% Success for Experimental Heart Catheter
Johnson & Johnson reported a 93.6% technical success rate in 30-day results from its FORWARD CAD study of the experimental Shockwave Javelin catheter. The...
Johnson & Johnson Pivots JLABS Incubator Strategy, Reduces Physical Labs
Johnson & Johnson evolves its JLABS incubator strategy, shifting from physical lab space to targeted scientific fields. JLABS has incubated approximately 1,200...
J&J Reports ERLEADA Combination Cuts Prostate Cancer Recurrence Risk 62%
Johnson & Johnson reported results from the Phase 3 PROTEUS substudy of ERLEADA® (apalutamide). Among patients with high-risk localized or locally advanced...
Johnson & Johnson's Experimental Prostate Cancer Drug Shows Promise in Early Trial
Johnson & Johnson announced promising early-stage trial results for JNJ-6143. This experimental drug is a once-daily oral treatment for prostate cancer. The...
Johnson & Johnson's Tecvayli Gains Expanded EU Approval as Monotherapy for Multiple Myeloma
The European Commission approved an expanded indication for Johnson & Johnson's Tecvayli (teclistamab). Tecvayli is approved as a monotherapy for adults with...
Johnson & Johnson's Oral Psoriasis Pill Icotyde Gains UK Approval
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Johnson & Johnson's daily oral pill, Icotyde (icotrokinra). The drug treats...
Smith & Nephew Merger Talks With J&J Collapse Over Leadership
Advanced merger talks between Smith & Nephew and Johnson & Johnson’s orthopaedics unit, DePuy Synthes, have collapsed. The reported sticking point was a...
🟢 Johnson & Johnson is trading 3.13% up today after favorable atrial-fibrillation treatment data
Johnson & Johnson is trading at $265.84, up +3.13%, with favorable atrial-fibrillation data cited as a positive contributor to shares’ sentiment. - In its...
Johnson & Johnson Says Tremfya Sustained Fistula Remission Through 48 Weeks
Johnson & Johnson reported positive 48-week results from the Phase 3 FUZION study of Tremfya (guselkumab) in adults with fistulizing Crohn’s disease, a severe...
Johnson & Johnson's Talvey Receives Positive EU Recommendation for Expanded Myeloma Use
The European Medicines Agency's CHMP positively recommended expanding the use of Johnson & Johnson's cancer drug, Talvey (talquetamab). The CHMP endorsed...
Johnson & Johnson Targets $100B Revenue, Fueled by Oncology Drug Growth
Johnson & Johnson raised its 2026 sales and earnings guidance after exceeding third-quarter analyst expectations. The company now projects operational sales...
J&J Beats Estimates But Shares Sink 4.3%: Can a Slimmer Company Outrun Geopolitical Drag and Earnings-Quality Questions?
Shares dropped sharply as Johnson & Johnson's Q3 report delivered a paradox: headline numbers that technically cleared the bar, but underlying details that...
🔴 Johnson & Johnson is trading 4.3% down today as Middle East conflict weighed on device sales
Johnson & Johnson is trading 4.3% down at $252.52 after its October 13 third-quarter report disappointed investors, with Middle East conflict weighing on...
Johnson & Johnson’s third quarter 2026 sales matched estimates at $25.4B while Innovative Medicine outperformed
Johnson & Johnson reported third quarter 2026 results featuring solid operational sales growth of 6.0%, driven by outperformance in its Innovative Medicine...
🔴 Johnson & Johnson is trading 3.13% down in pre-market following Q3 results
Johnson & Johnson is trading at $255.48, down 3.13% in pre-market following its Q3 earnings announcement. - Before the October 13 open, adjusted EPS was...
Johnson & Johnson Q3 2026 Earnings Preview: What Analysts Expect on October 13, 2026
Consensus estimates for Johnson & Johnson's third quarter of 2026 call for revenue of $25.40 billion and adjusted EPS of $2.66, as the stock trades near...
J&J Wins Injunction Blocking U.S. Simponi Biosimilar Launch
Johnson & Johnson’s Janssen unit secured a preliminary injunction blocking the U.S. launch of the first biosimilars for its immunology drugs Simponi and...
J&J Reports 50% Five-Year Treatment-Free Remission With CARVYKTI
Johnson & Johnson reported long-term results for CARVYKTI® (ciltacabtagene autoleucel) from the Phase 2 CARTITUDE-2 study. The findings showed that a single...